ACURA PHARMACEUTICALS, INC: debt financing — Acura borrows additional $300k from AD Pharma; warns of potential bankruptcy by early Nov 2025

ACURA PHARMACEUTICALS, INC

Principal balance on amended secured note reaches $8,994,279, with ~$865k accrued interest at 5.25%.
Three new $100k loans from AD Pharma (Sept 12, Oct 6, Oct 23 2025) used for day-to-day operations.
Without additional financing by early November 2025, company will need to scale back, furlough or terminate operations.
AD Pharma, which owns ~65% of Acura's common stock, is controlled by Mr. Schutte.
Interest rate on overdue amounts jumps to 7.5% per annum upon default.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of September 12, 2025, October 6, 2025 and October 23, 2025 we received loans of $100,000 from Abuse Deterrent Pharma, LLC

View on SEC.gov

304 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-101984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.